東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Essays in Health Economics.

Qiu, Yue.

Linked to FindBook

Google Book

Amazon

博客來

Essays in Health Economics.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Essays in Health Economics./
Author:	Qiu, Yue.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
Description:	97 p.
Notes:	Source: Dissertations Abstracts International, Volume: 82-08, Section: B.
Contained By:	Dissertations Abstracts International82-08B.
Subject:	Health care management. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28315941
ISBN:	9798569967780

Essays in Health Economics.
Qiu, Yue.

Essays in Health Economics. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 97 p.

Source: Dissertations Abstracts International, Volume: 82-08, Section: B.

Thesis (Ph.D.)--The University of Wisconsin - Madison, 2021.

This item must not be sold to any third party vendors.

The first chapter examines how regimen prices would change if drug companies could coordinate pricing the regimens they share. Typical HIV drug therapies are regimens that combine two or more drugs from different companies. Each company sets the price of its drug, and the regimen price is the sum of the component drugs' prices. Using individual pharmaceutical claims data, I estimate a structural demand model for HIV regimens. I then use the estimates to simulate counterfactuals under various scenarios. If companies sharing a regimen could coordinate and set a separate price for its shared regimen, the regimen price would drop in a range of 10% to 42%, and welfare would be higher.The second chapter evaluates the effect of drug non-adherence on hospitalization. High cholesterol is a serious health condition in the U.S. which puts patients at risk of heart diseases. Despite that taking anti-cholesterol drugs is important to manage cholesterol levels, the adherence is low. Non-adherence can be bad for patients' well-being and increase healthcare costs. With individual-level insurance claims data, I employ a propensity score matching to quantify the causal effect of non-adherence to anti-cholesterol drugs on coronary heart disease related hospitalizations. I find that non-adherent patients have an 18% increase in hospitalization rate compared with their matched adherent patients. Their average cost of hospitalization is also 38% higher.

ISBN: 9798569967780Subjects--Topical Terms:

2122906
Health care management.
Subjects--Index Terms:

Health economics

Essays in Health Economics.
LDR:02832nmm a2200469 4500 001 2285837
005 20220613065716.5
008 220803s2021 ||||||||||||||||| ||eng d
020 $a 9798569967780
035 $a (MiAaPQ)AAI28315941
035 $a AAI28315941
040 $a MiAaPQ $c MiAaPQ
100 1 $a Qiu, Yue. $3 3343189
245 1 0 $a Essays in Health Economics.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 97 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-08, Section: B.
500 $a Advisor: Sorensen, Alan T.
502 $a Thesis (Ph.D.)--The University of Wisconsin - Madison, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a The first chapter examines how regimen prices would change if drug companies could coordinate pricing the regimens they share. Typical HIV drug therapies are regimens that combine two or more drugs from different companies. Each company sets the price of its drug, and the regimen price is the sum of the component drugs' prices. Using individual pharmaceutical claims data, I estimate a structural demand model for HIV regimens. I then use the estimates to simulate counterfactuals under various scenarios. If companies sharing a regimen could coordinate and set a separate price for its shared regimen, the regimen price would drop in a range of 10% to 42%, and welfare would be higher.The second chapter evaluates the effect of drug non-adherence on hospitalization. High cholesterol is a serious health condition in the U.S. which puts patients at risk of heart diseases. Despite that taking anti-cholesterol drugs is important to manage cholesterol levels, the adherence is low. Non-adherence can be bad for patients' well-being and increase healthcare costs. With individual-level insurance claims data, I employ a propensity score matching to quantify the causal effect of non-adherence to anti-cholesterol drugs on coronary heart disease related hospitalizations. I find that non-adherent patients have an 18% increase in hospitalization rate compared with their matched adherent patients. Their average cost of hospitalization is also 38% higher.
590 $a School code: 0262.
650 4 $a Health care management. $3 2122906
650 4 $a Public health. $3 534748
650 4 $a Medicine. $3 641104
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Health economics
653 $a Industrial organization
653 $a Regimen prices
653 $a Drug companies
653 $a Pricing coordination
653 $a HIV drugs
653 $a HIV regimens
653 $a Hospitalization
653 $a Heart disease risk
653 $a Healthcare access
653 $a Anti-cholesterol drugs
690 $a 0501
690 $a 0769
690 $a 0564
690 $a 0572
690 $a 0573
710 2 $a The University of Wisconsin - Madison. $b Economics. $3 2094978
773 0 $t Dissertations Abstracts International $g 82-08B.
790 $a 0262
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28315941